FOLH1 and neoplasm: The benefit of an enhanced tumor uptake of long-circulating PSMA radioligands is, however, compromised by an increased retention of activity in healthy organs and tissues including the kidneys and bone marrow, which may limit the number of therapy cycles that can be applied.